Rabies Diagnostics Market Report 2025

The rabies diagnostics market size has grown strongly in recent years. It will grow from $1.68 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to globalization and travel patterns, one health approach adoption, regulatory standards development, advancements in animal testing, environmental influences.

The rabies diagnostics market size is expected to see strong growth in the next few years. It will grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing rabies incidence, environmental impact, cost efficiency, research and development, surveillance needs. Major trends in the forecast period include government initiatives and vaccination programs, globalization and travel, one health approach, public health concerns, remote and point-of-care diagnostics.

The rising incidence of rabies is anticipated to drive the growth of the rabies diagnostics market. Rabies is a preventable viral disease primarily transmitted through the bite of an infected animal. The rabies virus affects the central nervous systems of mammals, ultimately leading to brain damage and death. Rabies diagnostics involve various tests and techniques to detect the presence of the rabies virus in both humans and animals. Furthermore, the increasing number of cases of infectious diseases transmitted by animals has heightened the demand for rabies diagnostics. For example, a report from the Government of Canada, published in January 2023, indicated that 135 rabies samples were submitted in October 2022, followed by 159 samples in November 2022. Consequently, the growing prevalence of rabies is expected to boost the rabies diagnostics market.

The ongoing trend of urbanization is anticipated to fuel the growth of the rabies diagnostics market. Urbanization, driven by economic growth and industrialization, transforms rural areas into urban hubs. In this transition, rabies diagnostics play a pivotal role in swiftly detecting and managing rabies outbreaks within densely populated urban settings, safeguarding public health. As per an April 2023 report by the World Bank Group, over half of the global population currently resides in urban areas, a figure projected to climb to 6 billion by 2045, marking a 1.5-fold increase. Consequently, the surging urbanization serves as a catalyst propelling the rabies diagnostics market forward.

The growing emphasis on research and development (R&D) activities is expected to boost the rabies diagnostics market. R&D encompasses the systematic investigation, experimentation, and innovation aimed at creating new products, enhancing existing ones, or developing new technologies and methodologies. The rise in R&D activities is attributed to various factors, including heightened awareness of diseases, increased public and private investments, and health initiatives. These activities contribute to advancements in rabies diagnostics by identifying novel biomarkers and testing methods that improve sensitivity and specificity. This progress facilitates the development of rapid, cost-effective tests for the timely detection of the virus in clinical samples. For instance, in December 2023, Eurostat, the statistical office of the European Union based in Luxembourg, reported that the EU's R&D expenditure reached €352 billion ($384.42 billion) in 2022, reflecting a 6.34% increase from €331 billion ($361.48 billion) the previous year. Thus, the escalation of research and development activities is likely to drive growth in the rabies diagnostics market.

Product innovation stands as a prominent trend shaping the rabies diagnostics market. Pharmaceutical manufacturers globally are focusing on developing sophisticated testing techniques within analytical chemistry to deliver precise and cost-effective analytical solutions. These testing products seamlessly integrate into routine sample testing processes. For instance, in May 2022, Bio-Rad Laboratories Inc., a US-based technology developer, unveiled the CFX Duet Real-Time PCR system. This clinical diagnostic device aids researchers in creating singleplex and duplex quantitative PCR (qPCR) tests, boasting enhanced thermal performance, a patented optical shuttle system, and thermal gradient functionality for optimization.

Leading companies in the rabies diagnostics market are focused on developing innovative products, such as rabies antibody test kits, to maintain their competitive edge. A rabies antibody test kit is a diagnostic tool that detects antibodies in the blood to evaluate immunity levels or determine the need for additional rabies vaccinations. For example, in February 2024, BioStone Animal Health, a US-based diagnostic company, introduced AsurDx. This rabies antibody test kit utilizes a rapid and sensitive ELISA method to identify antibodies specific to the rabies virus in mammalian serum samples. It offers a cost-effective solution for assessing rabies immunity, making it suitable for both vaccinated animals and those at risk. Designed for ease of use, the kit provides reliable results, helping ensure that animals meet the standard of 0.5 international units (UL) per ml for effective immune response against rabies.

Major companies operating in the rabies diagnostics market are Bio-Rad Laboratories Inc., The Merck Group, Aviva Systems Biology Corporation, Creative Diagnostics, Demeditec Diagnostics GmbH, Abbexa Ltd., Norgen Biotek Corp., BioNote Inc., Express Biotech International Inc., MyBioSource Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Fluidigm Corp., Bio-X Diagnostics S.A., Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Heska Corporation, IDEXX Laboratories Inc., InBios International Inc., KHB Shanghai Kehua Bio-Engineering Co. Ltd., Meridian Bioscience Inc., MP Biomedicals LLC, Neogen Corporation, Randox Laboratories Ltd., SDIX LLC, Sigma-Aldrich Corporation, Virbac Animal health Pvt. Ltd., Zoetis Inc.

North America was the largest region in the rabies diagnostics market in 2024. The regions covered in the rabies diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rabies diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Rabies diagnostics involve identifying the Rabies disease based on observed conditions and symptoms. This preventable viral illness is commonly transmitted through the bite of a rabid animal. Diagnosis of Rabies typically involves locating the rabies virus within any part of the infected animal's brain. In humans, diagnosis includes testing saliva, serum, spinal fluid, and skin biopsies from hair follicles at the back of the neck.

The methods employed in Rabies diagnostics encompass various tests such as fluorescent antibody tests, immunohistochemical tests, amplification methods, histologic examinations, and serology tests. The fluorescent antibody test (FA) is based on detecting rabies virus proteins (antigen) in the tissues of infected animals. Technologies utilized include ELISA/immunohistochemistry, chromatography techniques, PCR, and others. These diagnostics are commonly employed by hospitals, diagnostic centers, cancer palliative care clinics, and diverse end-users, including pharmacies.

The rabies diagnostics market research report is one of a series of new reports that provides rabies diagnostics market statistics, including rabies diagnostics industry global market size, regional shares, competitors with a rabies diagnostics market share, detailed rabies diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the rabies diagnostics industry. This rabies diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rabies diagnostics market includes revenues earned by entities by providing diagnostic services such as reverse transcription followed by polymerase chain reaction (RT-PCR), virus isolation, and direct fluorescent antibody (DFA) tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.